Preferences for oral versus intravenous adjuvant chemotherapy among early breast cancer patients

被引:15
作者
Ishitobi, Makoto [1 ]
Shibuya, Kazuyo [2 ]
Komoike, Yoshifumi [1 ]
Koyama, Hiroki [1 ]
Inaji, Hideo [1 ]
机构
[1] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Breast & Endocrine Surg, Osaka 5378511, Japan
[2] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Nursing, Osaka 5378511, Japan
来源
PATIENT PREFERENCE AND ADHERENCE | 2013年 / 7卷
关键词
breast cancer; adjuvant; chemotherapy; patient preference; oral; intravenous; ADVANCED COLORECTAL-CANCER; RANDOMIZED-TRIALS; FLUOROURACIL; TEGAFUR; URACIL; WOMEN; CYCLOPHOSPHAMIDE; METHOTREXATE; REGIMENS; HER2;
D O I
10.2147/PPA.S52687
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: The purpose of this study was to evaluate preferences for oral versus intravenous adjuvant chemotherapy among early breast cancer patients (UMIN-CTR number UMIN000004696). Patients and methods: Eighty-two postmenopausal women with estrogen receptor-positive, human epidermal growth-factor receptor 2-negative breast cancer who had completed adjuvant chemotherapy were asked about their preferred route of administration of chemotherapy and the reason. Women also answered questions about their physical and psychological status and quality of life during chemotherapy. Results: Patients who had received oral chemotherapy preferred it more frequently than those who had received intravenous chemotherapy (100% versus 37%, respectively, chi-square = 15.5; P<0.001). Patients who preferred the same route of administration of chemotherapy as they had previously received showed a significantly better psychological status during chemotherapy compared with those who preferred a different route. Conclusion: Our study showed that preferences for oral and intravenous chemotherapy strongly depended on the actual prior administration of chemotherapy and patients' own experiences during chemotherapy.
引用
收藏
页码:1201 / 1206
页数:6
相关论文
共 13 条
  • [1] Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
    Albain, K.
    Anderson, S.
    Arriagada, R.
    Barlow, W.
    Bergh, J.
    Bliss, J.
    Buyse, M.
    Cameron, D.
    Carrasco, E.
    Clarke, M.
    Correa, C.
    Coates, A.
    Collins, R.
    Costantino, J.
    Cutter, D.
    Cuzick, J.
    Darby, S.
    Davidson, N.
    Davies, C.
    Davies, K.
    Delmestri, A.
    Di Leo, A.
    Dowsett, M.
    Elphinstone, P.
    Evans, V.
    Ewertz, M.
    Gelber, R.
    Gettins, L.
    Geyer, C.
    Goldhirsch, A.
    Godwin, J.
    Gray, R.
    Gregory, C.
    Hayes, D.
    Hill, C.
    Ingle, J.
    Jakesz, R.
    James, S.
    Kaufmann, M.
    Kerr, A.
    MacKinnon, E.
    McGale, P.
    McHugh, T.
    Norton, L.
    Ohashi, Y.
    Paik, S.
    Pan, H. C.
    Perez, E.
    Peto, R.
    Piccart, M.
    [J]. LANCET, 2012, 379 (9814) : 432 - 444
  • [2] Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin:: a randomised crossover trial in advanced colorectal cancer
    Borner, MM
    Schöffski, P
    de Wit, R
    Caponigro, F
    Comella, G
    Sulkes, A
    Greim, G
    Peters, GJ
    van der Born, K
    Wanders, J
    de Boer, RF
    Martin, C
    Fumoleau, P
    [J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 (03) : 349 - 358
  • [3] Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer
    Fallowfield, L
    Atkins, L
    Catt, S
    Cox, A
    Coxon, C
    Langridge, C
    Morris, R
    Price, M
    [J]. ANNALS OF ONCOLOGY, 2006, 17 (02) : 205 - 210
  • [4] Same gain, less pain: potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer
    Fallowfield, L
    McGurk, R
    Dixon, M
    [J]. EUROPEAN JOURNAL OF CANCER, 2004, 40 (16) : 2403 - 2410
  • [5] HER2 status and efficacy of adjuvant anthracyclines in early breast cancer:: A pooled analysis of randomized trials
    Gennari, Alessandra
    Sormani, Maria Pia
    Pronzato, Paolo
    Puntoni, Matteo
    Colozza, Mariantonietta
    Pfeffer, Ulrich
    Bruzzi, Paolo
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (01): : 14 - 20
  • [6] HER2 and response to paclitaxel in node-positive breast cancer
    Hayes, Daniel F.
    Thor, Ann D.
    Dressler, Lynn G.
    Weaver, Donald
    Edgerton, Susan
    Cowan, David
    Broadwater, Gloria
    Goldstein, Lori J.
    Martino, Silvana
    Ingle, James N.
    Henderson, I. Craig
    Norton, Larry
    Winer, Eric P.
    Hudis, Clifford A.
    Ellis, Matthew J.
    Berry, Donald A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (15) : 1496 - 1506
  • [7] Quality of Life of Older Patients With Early-Stage Breast Cancer Receiving Adjuvant Chemotherapy: A Companion Study to Cancer and Leukemia Group B 49907
    Kornblith, Alice B.
    Lan, Lan
    Archer, Laura
    Partridge, Ann
    Kimmick, Gretchen
    Hudis, Clifford
    Winer, Eric
    Casey, Rebecca
    Bennett, Samantha
    Cohen, Harvey Jay
    Muss, Hyman B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (08) : 1022 - 1028
  • [8] Patient preferences for oral versus intravenous palliative chemotherapy
    Liu, G
    Franssen, E
    Fitch, MI
    Warner, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) : 110 - 115
  • [9] Therapeutic Usefulness of Postoperative Adjuvant Chemotherapy with Tegafur-Uracil (UFT) in Patients with Breast Cancer: Focus on the Results of Clinical Studies in Japan
    Nakayama, Takahiro
    Noguchi, Shinzaburo
    [J]. ONCOLOGIST, 2010, 15 (01) : 26 - 36
  • [10] Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: a pooled analysis of two randomized controlled trials (N•SAS-BC 01 trial and CUBC trial)
    Ohashi, Yasuo
    Watanabe, Toru
    Sano, Muneaki
    Koyama, Hiroki
    Inaji, Hideo
    Suzuki, Takaichiro
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (03) : 633 - 641